Table 3. Interferon in epithelioid hemangioendothelioma.
| Author | Reference | Primary site | Interferon | Dose and schedule | Outcome | Follow-up |
|---|---|---|---|---|---|---|
| Radzikowaska et al. | 19 | Thoracic | Alpha-2a | 3 million units, 3 times a week |
Stable disease | 3 months |
| Saleiro et al. | 20 | Thoracic | Alpha 2b | - | Progressive disease | 9 months |
| Calabro et al. | 21 | Thoracic | Alpha 2a | - | Stable disease | - |
| Hassan et al. | 22 | Thyroid | Alpha | 3 million units, 5 times a week |
Progressive disease | 2 months |
| Marsh et al. | 23 | Breast | Alpha | 3 millon units, 5 days a week for 1 year |
Complete response | 84 months |
| Al-Sharim et al. | 24 | Thoracic | Alpha | 7 million units, 3 times a week. |
Progressive disease | 2 months |
| Kayler et al. | 25 | Hepatic | Alpha-2b | 3 million units daily | Partial response | 4 months |